L-glutamic acid producing recombinant microorganism and method for producing L-glutamic acid using the same
By introducing the SbtA protein or its encoding polynucleotide into Corynebacterium, the microorganism enhances carbon dioxide utilization, leading to high-yield L-glutamic acid production suitable for industrial use.
Patent Information
- Application Number
- JP2023514716
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-09-09
- Filing Date
- 2021-06-30
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-06-30
AI Technical Summary
Current methods for producing L-glutamic acid are not efficient enough to achieve high concentrations, necessitating the development of a microorganism that can enhance the production yield.
A recombinant microorganism of the genus Corynebacterium is engineered to express an SbtA protein or a polynucleotide encoding the SbtA protein, which is a bicarbonate transporter, to improve carbon dioxide utilization and enhance L-glutamic acid production.
The engineered microorganism achieves high-yield production of L-glutamic acid, suitable for industrial applications.
Smart Images

Figure 0007584632000007 
Figure 0007584632000001 
Figure 0007584632000002
Abstract
Description
[Technical field]
[0001] The present application relates to an L-glutamic acid producing microorganism containing an SbtA protein or a polynucleotide encoding the SbtA protein, and a method for producing L-glutamic acid using the same. [Background technology]
[0002] L-glutamic acid is a representative amino acid produced by fermentation, has a unique taste, and is one of the important amino acids widely used in the food industry, pharmaceutical industry, animal feed industry, etc. Methods for producing L-glutamic acid using microorganisms such as Corynebacterium, Escherichia coli, Bacillus, Streptomyces, Penicillium, Klebsiella, Erwinia, and Pantoea are known (Patent Documents 1 and 2).
[0003] Currently, various studies are being conducted to develop microorganisms and fermentation process technologies that produce L-glutamic acid with high efficiency. For example, target substance-specific approaches such as increasing the expression of genes encoding enzymes involved in amino acid biosynthesis in Corynebacterium microorganisms and removing genes unnecessary for amino acid biosynthesis are mainly used to improve the L-glutamic acid production yield (Patent Documents 3 and 4). [Prior art documents] [Patent documents]
[0004] [Patent Document 1] U.S. Pat. No. 3,220,929 [Patent Document 2] U.S. Patent No. 6,682,912 [Patent Document 3] U.S. Patent No. 9,109,242 [Patent Document 4] U.S. Patent No. 8,030,036 [Patent Document 5] U.S. Patent No. 7,662,943 [Patent Document 6] U.S. Patent No. 10,584,338 [Patent Document 7] U.S. Patent No. 10,273,491 [Patent Document 8] Republic of Korea Patent Registration No. 10-0292299 [Patent Document 9] Republic of Korea Patent Registration No. 10-0620092 [Patent Document 10] International Publication No. WO 2006 / 0065095 [Non-Patent Document]
[0005] [Non-Patent Document 1] J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory press, Cold Spring Harbor, New York, 1989 [Non-Patent Document 2] F.M. Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, Inc., New York, 9.50 - 9.51, 11.7 - 11.8 [Non-Patent Document 3] Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444 [Non-Patent Document 4] Rice et al., 2000, Trends Genet. 16: 276 - 277 [Non-Patent Document 5] Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453
Non-licensed Document 6
Non-licensed Document 7
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
[0006] As a result of extensive efforts to produce high-concentration L-glutamic acid, the present inventors have developed a Corynebacterium microorganism capable of producing high-concentration L-glutamic acid by introducing a foreign protein, thereby completing the present application. [Means for solving the problem]
[0007] An object of the present application is to provide a recombinant microorganism of the genus Corynebacterium that produces L-glutamic acid, comprising an SbtA protein or a polynucleotide encoding the SbtA protein.
[0008] Another object of the present application is to provide a method for producing L-glutamic acid, which comprises the step of culturing in a medium an L-glutamic acid-producing recombinant Corynebacterium microorganism containing the SbtA protein or a polynucleotide encoding the SbtA protein. Effect of the Invention
[0009] The L-glutamic acid-producing recombinant Corynebacterium microorganism containing the SbtA protein of the present application or a polynucleotide encoding the SbtA protein is capable of producing L-glutamic acid in high yields and is useful for the industrial production of L-glutamic acid. [Brief description of the drawings]
[0010] [Figure 1] FIG. 1 is a schematic diagram of the pDCM2 plasmid. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] These will be described in detail below. Note that each description and embodiment disclosed in this application also applies to other descriptions and embodiments. In other words, all combinations of various elements disclosed in this application are included in this application. In addition, this application is not limited to the following specific description. Furthermore, a person skilled in the art will be able to recognize and confirm many equivalents to the specific aspects of this application described in this application using only routine experimentation. Furthermore, the equivalents are also intended to be included in this application.
[0012] To achieve the object of the present application, one aspect of the present application provides a recombinant Corynebacterium microorganism capable of producing L-glutamic acid, comprising an SbtA protein or a polynucleotide encoding the SbtA protein.
[0013] The "SbtA protein" in this application is a bicarbonate transporter that transports bicarbonate, HCO3, which is membrane-impermeable. - It promotes the passage of bicarbonate through the membrane, contributing to the acceleration of carbon dioxide (CO2) processing, and is one of the proteins expressed for the capture and efficient use of carbon dioxide. Bicarbonate transporters include SbtA protein and BicA protein, which transport bicarbonate into cells, resulting in the accumulation of bicarbonate within the cells.
[0014] In the present application, the SbtA protein may be a protein derived from a microorganism different from the microorganism of the present application, or may be a protein different from a protein endogenously present in the microorganism of the present application.
[0015] In the present application, the SbtA protein is a protein derived from Cyanobacteria, but is not limited thereto. Specifically, the SbtA protein may be a protein derived from a microorganism of the genus Synechocystis, more specifically, a protein derived from a microorganism of the genus Synechocystis, Synechocystis sp. PCC 6803 or Synechocystis sp. PCC 6714.
[0016] The SbtA protein of the present application may comprise an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1. The amino acid sequence of SEQ ID NO: 1 may be obtained from the publicly known database, NIH GenBank. Specifically, the amino acid sequence having 90% or more identity to SEQ ID NO: 1 of the present application may be an amino acid sequence having 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 96.26% or more, 97% or more, 97.5% or more, 97.7% or more, 97.8% or more, 98% or more, 98.5% or more, 98.7% or more, 98.8% or more, 99% or more, 99.5% or more, 99.7% or more, 99.8% or more or more, and less than 100% homology or identity to SEQ ID NO: 1 of the present application. For example, an amino acid sequence having a homology or identity of 90% or more and less than 100% to the amino acid sequence of SEQ ID NO: 1 may be the amino acid sequence of SEQ ID NO: 30. Needless to say, the SbtA protein of the present application also includes proteins having an amino acid sequence in which a portion of the sequence has been deleted, modified, substituted, conservatively substituted, or added, so long as the amino acid sequence has such homology or identity and exhibits the same or corresponding activity as the SbtA protein or bicarbonate transporter activity.
[0017] The SbtA protein of the present application may have an amino acid sequence having 90% or more identity with the amino acid sequence of SEQ ID NO: 1. The SbtA protein of the present application may have an amino acid sequence having 90% or more identity with the amino acid sequence of SEQ ID NO: 1, may consist of the amino acid sequence, or may be essentially composed of the amino acid sequence. The SbtA protein of the present application does not exclude those having meaningless sequence additions before or after the amino acid sequence of SEQ ID NO: 1 (i.e., addition of sequences that do not change the function of the protein to the N-terminus and / or C-terminus of the amino acid sequence), naturally occurring mutations, silent mutations, or conservative substitutions thereof.
[0018] The term "conservative substitution" in the SbtA protein of the present application means that an amino acid is replaced with another amino acid having similar structural and / or chemical properties. Such amino acid substitutions may generally be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic nature of the residues. Typically, conservative substitutions have little or no effect on the activity of a protein or polypeptide.
[0019] In the present application, the polynucleotide encoding the SbtA protein may be an sbtA gene. The polynucleotide encoding the SbtA protein may be derived from a cyanobacterium. Specifically, the polynucleotide encoding the SbtA protein of the present application may include a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1. Specifically, the polynucleotide encoding the SbtA protein of the present application includes, but is not limited to, the nucleotide sequence of SEQ ID NO: 2, the nucleotide sequence of SEQ ID NO: 31, or a nucleotide sequence having 90% or more identity thereto and encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1. The polynucleotide including a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1 may be a polynucleotide having a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1, a polynucleotide consisting of a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1, or a polynucleotide essentially composed of a nucleotide sequence encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1.
[0020] In the present application, the term "polynucleotide" refers to a nucleotide polymer in which nucleotide monomers are linked in a long chain by covalent bonds, and refers to a DNA chain longer than a certain length.
[0021] It goes without saying that the polynucleotide of the present application includes a polynucleotide in which a part of the nucleotide sequence is deleted, modified, substituted, conservatively substituted or added, so long as it contains the nucleotide sequence of SEQ ID NO: 2, the nucleotide sequence of SEQ ID NO: 3, the nucleotide sequence of SEQ ID NO: 31, or a nucleotide sequence having 90% or more identity thereto and encoding an amino acid sequence having 90% or more identity to the amino acid sequence of SEQ ID NO: 1. In the polynucleotide of the present application, a "conservative substitution" means that a certain base is replaced with another base having similar structural and / or chemical properties.
[0022] The polynucleotide of the present application may be modified in various ways in the coding region to the extent that the polynucleotide sequence is not changed, taking into account codon degeneracy or preferred codons in the organism in which the polynucleotide is to be expressed. Specifically, the polynucleotide of the present application may be a polynucleotide comprising the nucleotide sequence of SEQ ID NO:2.
[0023] Furthermore, the polynucleotide of the present application may be any polynucleotide sequence that can improve L-glutamic acid producing ability by hybridizing under stringent conditions with a probe prepared from a known sbtA gene sequence, for example, a complementary sequence to all or a part of the aforementioned base sequence, rather than a sequence that naturally exists in the microorganism to which it is introduced.
[0024] Furthermore, the polynucleotide of the present application may be any sequence that can hybridize under stringent conditions with a probe prepared from a known gene sequence, for example, a complementary sequence to all or a part of the polynucleotide sequence of the present application. The term "stringent conditions" refers to conditions that allow specific hybridization between polynucleotides. Such conditions are specifically described in the literature (see Non-Patent Documents 1 and 2). For example, the conditions include conditions under which polynucleotides having high homology or identity, such as polynucleotides having a homology or identity of 70% or more, 75% or more, 76% or more, 85% or more, 90% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more, hybridize with each other, but polynucleotides having lower homology or identity than that do not hybridize with each other, or conditions under which washing is performed once, specifically two to three times, at a salt concentration and temperature equivalent to those used in normal Southern hybridization, specifically 60°C, 1×SSC, 0.1% SDS, specifically 60°C, 0.1×SSC, 0.1% SDS, more specifically 68°C, 0.1×SSC, 0.1% SDS.
[0025] Hybridization requires that two nucleic acids have complementary sequences, even though mismatches between bases are possible depending on the stringency of hybridization. "Complementary" is used to describe the relationship between nucleotide bases that can hybridize with each other. For example, in DNA, adenosine is complementary to thymine, and cytosine is complementary to guanine. Thus, the polynucleotides of the present application may include isolated nucleic acid fragments that are complementary to the entire sequence, as well as substantially similar nucleic acid sequences.
[0026] Specifically, polynucleotides having homology or identity to the polynucleotides of the present application can be detected using the hybridization conditions described above, in which the hybridization step is performed at a Tm value of 55° C. The Tm value may be, but is not limited to, 60° C., 63° C., or 65° C., and may be appropriately adjusted by those skilled in the art depending on the purpose.
[0027] The appropriate stringency for hybridizing the polynucleotides depends on the length of the polynucleotides and the degree of complementation, variables known in the art (eg, Non-Patent Document 1).
[0028] In this application, "homology" or "identity" refers to the degree to which two given amino acid or nucleotide sequences are similar, and can be expressed as a percentage. Homology and identity are often used interchangeably.
[0029] Conserved Polynucleotides Sequence homology or identity of a gene or polypeptide may be determined by standard sequence algorithms, with default gap penalties established by the program used. Substantially homologous or identical sequences will generally hybridize to all or a portion of the sequence under moderate or high stringent conditions. Hybridization, of course, also includes hybridization to polynucleotides having common codons or codons that take into account codon degeneracy in the polynucleotide.
[0030] Whether any two polynucleotide or polypeptide sequences have homology, similarity or identity can be determined using known computer algorithms such as the "FASTA" program with default parameters as in, for example, Non-Patent Document 3. Alternatively, it can be determined using the Needleman-Wunsch algorithm (Non-Patent Document 5), as implemented in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Non-Patent Document 4) (version 5.0.0 or later), which includes the GCG program package (Non-Patent Document 6), BLASTP, BLASTN, FASTA (Non-Patent Documents 7, 8 and 9). For example, BLAST or Clustal W from the National Center for Biotechnology Information can be used to determine homology, similarity or identity.
[0031] Homology, similarity or identity of polynucleotides or polypeptides can be determined by comparing sequence information using a GAP computer program such as GAP (1999) (1999) (1999) (1999) (1999). Briefly, the GAP program defines the number of similar sequence symbols (i.e., nucleotides or amino acids) divided by the total number of symbols in the shorter of the two sequences. Default parameters for the GAP program include (1) a binary comparison matrix (identity takes a value of 1 and non-identity takes a value of 0) and a weighted comparison matrix (or EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix) of GAP (1999) (1999) (2) a penalty of 3.0 for each gap and an additional penalty of 0.10 for each symbol in each gap (or a gap open penalty of 10 and a gap extension penalty of 0.5), and (3) no penalty for terminal gaps.
[0032] The SbtA protein contained in the recombinant microorganism of the present application is expressed in a microorganism of the genus Corynebacterium by conventional methods known in the art.
[0033] In the present application, the term "expression" of a protein refers to a state in which a target protein is introduced into a microorganism or modified to be expressed in the microorganism. For the purposes of the present application, the "target protein" may be the SbtA protein described above.
[0034] In the present application, the "introduction" of a protein means that the activity of a protein is introduced into a microorganism that does not have the activity of the specific protein. This is also called enhancing the activity of a protein in a microorganism that does not have the activity of the specific protein.
[0035] The introduction of the protein is carried out by introducing into the host cell a foreign polynucleotide encoding a protein exhibiting the same / similar activity as the protein, or a codon-optimized mutant polynucleotide thereof. The origin or sequence of the foreign polynucleotide is not limited as long as it exhibits the same / similar activity as the protein. In addition, the codons of the introduced foreign polynucleotide may be optimized and introduced into the host cell so that optimized transcription and translation are performed in the host cell. The introduction can be carried out by a person skilled in the art by appropriately selecting a known transformation method, and the introduced polynucleotide is expressed in the host cell as described above, thereby producing a protein and enhancing its activity.
[0036] In the present application, "enhancement" of a polypeptide activity means increasing the activity of the polypeptide compared to its endogenous activity. The enhancement is used interchangeably with activation, up-regulation, overexpression, increase, etc. Here, activation, enhancement, up-regulation, overexpression, and increase all include the display of an activity that was not originally present, and the improvement of activity compared to the endogenous activity or activity before modification. The "endogenous activity" means the activity of a specific polypeptide that was originally possessed by a parent strain or an unmodified microorganism before the trait change when the trait is changed due to genetic mutation caused by natural or artificial factors. This is used interchangeably with "activity before modification." The "enhancement," "up-regulation," "overexpression," or "increase" of a polypeptide activity compared to its endogenous activity means that the activity and / or concentration (expression level) of a specific polypeptide is improved compared to the activity and / or concentration (expression level) that was originally possessed by a parent strain or an unmodified microorganism before the trait change.
[0037] The enhancement may be achieved by introducing a foreign polypeptide, or by enhancing the activity and / or concentration (expression level) of an endogenous polypeptide. Whether the activity of the polypeptide has been enhanced can be confirmed by an increase in the level of activity of the polypeptide, the expression level, or the amount of a product produced from the polypeptide.
[0038] To enhance the activity of the polypeptide, various methods well known in the art can be applied, and any method may be used as long as it can enhance the activity of the target polypeptide compared to that of the microorganism before modification. Specifically, the method is a conventional method in molecular biology that uses genetic engineering and / or protein engineering well known to those skilled in the art, but is not limited to these (e.g., Non-Patent Documents 13 and 14, etc.).
[0039] Specifically, the enhancement of the polypeptide of the present application is carried out by 1) increasing the intracellular copy number of a polynucleotide encoding the polypeptide, 2) replacing the expression regulatory region of a gene on a chromosome encoding the polypeptide with a sequence having stronger activity, 3) modifying the nucleotide sequence encoding the start codon or 5'UTR region of a gene transcript encoding the polypeptide, 4) modifying the amino acid sequence of the polypeptide so that the activity of the polypeptide is enhanced, 5) modifying the polynucleotide sequence encoding the polypeptide so that the activity of the polypeptide is enhanced (for example, modifying the polynucleotide sequence of the polypeptide gene so as to encode a polypeptide modified so that the activity of the polypeptide is enhanced), 6) introducing a foreign polypeptide exhibiting the activity of the polypeptide or a foreign polynucleotide encoding the same, 7) optimizing the codons of the polynucleotide encoding the polypeptide, 8) analyzing the tertiary structure of the polypeptide and selectively modifying or chemically modifying exposed portions, or 9) a combination of two or more selected from 1) to 8) above, but is not particularly limited thereto.
[0040] More specifically, the above 1) increasing the intracellular copy number of a polynucleotide encoding a polypeptide may be achieved by introducing into a host cell a vector to which a polynucleotide encoding the polypeptide is operably linked, the vector replicating and functioning independently of the host. Alternatively, the above may be achieved by introducing one or more copies of the polynucleotide encoding the polypeptide into a chromosome in the host cell. The introduction into a chromosome is achieved by introducing into the host cell a vector capable of inserting the polynucleotide into a chromosome in the host cell, but is not limited thereto.
[0041] The expression regulatory region (or expression regulatory sequence) of the gene on the chromosome encoding the polypeptide (2) may be replaced with a sequence having stronger activity, for example, by generating a mutation in the sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so that the activity of the expression regulatory region is further enhanced, or by replacing the expression regulatory region with a sequence having stronger activity. The expression regulatory region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, a sequence regulating the termination of transcription and translation, and the like. For example, the expression regulatory region may be replaced with a strong promoter, but is not limited to this.
[0042] Examples of known strong promoters include, but are not limited to, the CJ1 to CJ7 promoters (Patent Document 5), the lac promoter, the trp promoter, the trc promoter, the tac promoter, the lambda phage PR promoter, the PL promoter, the tet promoter, the gapA promoter, the SPL7 promoter, the SPL13 (sm3) promoter (Patent Document 6), the O2 promoter (Patent Document 7), the tkt promoter, and the yccA promoter.
[0043] The modification of the nucleotide sequence encoding the start codon or 5'UTR region of the gene transcription product encoding the polypeptide (3) can be carried out, for example, by substituting a nucleotide sequence encoding another start codon that has a higher expression rate of the polypeptide compared to the endogenous start codon, but is not limited to this.
[0044] The modification of the amino acid sequence or polynucleotide sequence in 4) and 5) above can be performed by, but is not limited to, generating a sequence mutation in the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so as to enhance the activity of the polypeptide, or by replacing the amino acid sequence or polynucleotide sequence with an improved amino acid sequence or polynucleotide sequence having a higher activity, or an improved amino acid sequence or polynucleotide sequence having an increased activity. Specifically, the replacement can be performed by, but is not limited to, inserting the polynucleotide into a chromosome by homologous recombination. Here, the vector used may further include a selection marker for checking whether or not it has been inserted into a chromosome. The selection marker is as described above.
[0045] The above 6) introduction of a foreign polynucleotide exhibiting the activity of a polypeptide is carried out by introducing into a host cell a foreign polynucleotide encoding a polypeptide exhibiting the same / similar activity as the above polypeptide. The origin or sequence of the foreign polynucleotide is not limited as long as it exhibits the same / similar activity as the above polypeptide. The introduction can be carried out by a person skilled in the art by appropriately selecting a known transformation method, and the introduced polynucleotide is expressed in the host cell as described above, thereby producing a polypeptide and increasing its activity.
[0046] 7) Optimizing the codons of a polynucleotide encoding a polypeptide can be carried out by optimizing the codons of an endogenous polynucleotide so as to increase transcription or translation in a host cell, or by optimizing the codons of an exogenous polynucleotide so as to perform optimized transcription or translation in a host cell.
[0047] 8) Analyzing the tertiary structure of a polypeptide and selecting and altering or chemically modifying an exposed portion thereof can be carried out, for example, by comparing the sequence information of the polypeptide to be analyzed with a database in which sequence information of known proteins is stored, determining candidates for template proteins according to the degree of sequence similarity, confirming the structure based on the candidates, and selecting and altering or modifying the exposed portion to be altered or chemically modified.
[0048] Such enhancement of polypeptide activity can be achieved by increasing the activity, concentration, or expression amount of the corresponding polypeptide compared to the activity or concentration of the polypeptide expressed in a wild-type or unmodified microbial strain, or by increasing the amount of a product produced from the polypeptide. , but is not limited to these.
[0049] In the microorganism of the present application, modification of a part or the whole of a polynucleotide can be induced by (a) homologous recombination using a vector for chromosomal insertion in the microorganism, or genome editing using engineered nuclease (e.g., CRISPR-Cas9), and / or (b) light and / or chemical treatment, but is not limited thereto. Methods for modifying a part or the whole of the gene include methods using DNA recombination techniques. For example, a nucleotide sequence or vector containing a nucleotide sequence homologous to a target gene is introduced into the microorganism to cause homologous recombination, thereby deleting a part or the whole of the gene. The introduced nucleotide sequence or vector may contain, but is not limited to, a dominant selection marker.
[0050] In this application, the term "vector" refers to a DNA product containing a target polynucleotide sequence operably linked to a suitable regulatory sequence so that the target gene can be introduced into a suitable host. The regulatory sequence includes a promoter to initiate transcription, an optional operator sequence to regulate the transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence to regulate the termination of transcription and translation. When transformed into a suitable host cell, the vector can replicate or function independently of the host genome and is integrated into the genome itself. For example, a vector for intracellular chromosomal introduction can replace a target polynucleotide with a mutated polynucleotide in a chromosome. The insertion of the polynucleotide into a chromosome can be performed by any method known in the art, such as, but not limited to, homologous recombination.
[0051] The vector of the present application is not particularly limited, and any vector known in the art may be used. Examples of commonly used vectors include plasmids, cosmids, viruses, and bacteriophages in a natural or recombinant state. For example, pWE15, M13, MBL3, MBL4, IXII, ASHII, APII, t10, t11, Charon4A, Charon21A, etc. may be used as phage or cosmid vectors, and pBR, pUC, pBluescriptII, pGEM, pTZ, pCL, pET, etc. may be used as plasmid vectors. Specifically, pDZ, pACYC177, pACYC184, pCL, pECCG117, pUC19, pBR322, pMW118, pCC1BAC vectors, etc. may be used. More specifically, the vector used in this application is pDCM2 (Figure 1, sequence number 32) which was constructed for the introduction and replacement of genes into the Corynebacterium chromosome, but is not particularly limited thereto, and any known expression vector may be used.
[0052] In the present application, "transformation" means introducing a vector containing a polynucleotide encoding a target protein into a host cell, thereby expressing the protein encoded by the polynucleotide in the host cell. The transformed polynucleotide may be any polynucleotide that is expressed in the host cell, regardless of whether it is inserted into the chromosome of the host cell or located extrachromosomally. The polynucleotide may include DNA or RNA that encodes the target protein. The polynucleotide may be introduced in any form as long as it is introduced into the host cell and expressed. For example, the polynucleotide is introduced into the host cell in the form of an expression cassette, which is a genetic structure containing all elements necessary for its own expression. Typically, the expression cassette contains a promoter, a transcription termination signal, a ribosome binding site, and a translation termination signal operably linked to the polynucleotide. The expression cassette may be in the form of a self-replicating expression vector. The polynucleotide may be introduced into the host cell in its own form and operably linked to a sequence necessary for expression in the host cell, but is not limited thereto.
[0053] In addition, "operably linked" in the present application means that the gene sequence is functionally linked to a promoter sequence that initiates and mediates transcription of a polynucleotide encoding a target protein of the present application.
[0054] The method for transforming the vector of the present application may be any method for introducing a nucleic acid into a cell, and may be carried out by selecting a standard technique suitable for the host cell as known in the art, such as, but not limited to, electroporation, calcium phosphate (CaPO4) precipitation, calcium chloride (CaCl2) precipitation, microinjection, polyethylene glycol (PEG) method, DEAE-dextran method, cationic liposome method, lithium acetate-DMSO method, etc.
[0055] The term "recombinant microorganism" in this application includes all microorganisms that have been artificially genetically modified, and may be a microorganism in which a specific mechanism has been weakened or enhanced by, for example, inserting an exogenous gene to express an exogenous protein or enhancing or weakening the activity of an endogenous gene, and may be a microorganism that has been genetically modified to produce a target protein or product.
[0056] For example, a recombinant microorganism of the present application is, but is not limited to, a microorganism genetically modified with at least one of an SbtA protein or a polynucleotide encoding an SbtA protein and a vector comprising said polynucleotide, a microorganism modified to express said protein or a polynucleotide encoding it, a recombinant microorganism that expresses said protein or a polynucleotide encoding it, or a recombinant microorganism that has the activity of said protein.
[0057] Furthermore, the recombinant microorganism of the present application may be a microorganism whose L-glutamic acid producing ability has been enhanced by further enhancing the activity of a part of the protein in the L-glutamic acid biosynthetic pathway or by further weakening the activity of a part of the protein in the L-glutamic acid degradation pathway.
[0058] Specifically, the microorganism of the present application may be a microorganism in which the OdhA protein is further weakened. More specifically, the microorganism of the present application may be a microorganism in which the odhA gene is deleted. The sequence of the OdhA protein is obtained from GenBank of NCBI, a known database, for example, GenBank Accession No. WP_060564343.1, but is not limited thereto, and any protein having the same activity as the OdhA protein may be used.
[0059] However, the weakening of the OdhA protein or the deletion of the odhA gene described above is merely an example and is not limited thereto. The microorganism of the present application may be any of various known microorganisms in which the protein activity of the L-glutamic acid biosynthetic pathway is enhanced or in which the protein activity of the degradation pathway is weakened.
[0060] As yet another example, the recombinant microorganism of the present application may be a parent strain of a microorganism that has been treated with a compound to enable production of L-glutamic acid. Specifically, the compound is, but is not limited to, N-Methyl-N'-nitro-N-nitrosoguanidine (NTG).
[0061] For the purposes of this application, a recombinant microorganism in this application means a microorganism having improved L-glutamic acid production ability compared to a parent strain or an unmodified microorganism before transformation. The term "unmodified microorganism" does not exclude strains containing mutations that may occur naturally in microorganisms, but means a natural microorganism itself, a wild-type microorganism itself, a microorganism before the expression level of a gene involved in the L-glutamic acid biosynthetic pathway is regulated, or a microorganism before the sbtA gene that does not exist endogenously is introduced.
[0062] In the present application, the parent strain may be, but is not limited to, wild-type Corynebacterium glutamicum ATCC13869, the Corynebacterium glutamicum in which OdhA has been weakened, the Corynebacterium glutamicum ATCC13869 strain in which odhA has been deleted, or Corynebacterium glutamicum BL2 (Accession No. KFCC-11074, Patent Document 8) obtained by treating the Corynebacterium glutamicum KFCC10656 strain with a mutagen such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG).
[0063] In the present application, the term "attenuation" of a polypeptide refers to a concept that includes all of the following: a decrease in activity compared to the endogenous activity, or the absence of activity. The term "attenuation" is also used interchangeably with other terms such as inactivation, deficiency, down-regulation, decrease, reduction, and attenuation.
[0064] The weakening includes cases where the activity of the polypeptide itself is reduced or eliminated compared to the activity of the polypeptide originally possessed by the microorganism due to mutation of the polynucleotide encoding the polypeptide, cases where the overall level and / or concentration (expression amount) of the polypeptide activity in the cell is reduced compared to the natural strain due to inhibition of gene expression of the encoding polynucleotide or inhibition of translation into the polypeptide, cases where the polynucleotide is not expressed at all, and / or cases where the polynucleotide is expressed but the polypeptide activity is absent. The "endogenous activity" refers to the activity of a specific polypeptide originally possessed by a parent strain, wild type, or unmodified microorganism before the trait change when the trait is changed by genetic mutation due to natural or artificial factors. This is used interchangeably with "activity before modification." The activity of a polypeptide is "weakened, inactivated, deficient, reduced, down-regulated, decreased, attenuated" compared to the endogenous activity means that the activity of a specific polypeptide is decreased compared to the activity of a specific polypeptide originally possessed by a parent strain or unmodified microorganism before the trait change.
[0065] Such attenuation of the activity of a polypeptide can be achieved by applying various methods well known in the art, including, but not limited to, those described above (eg, Non-Patent Documents 14 and 15).
[0066] Specifically, the attenuation of a polypeptide of the present application can be achieved by 1) deleting all or a part of a gene encoding the polypeptide, 2) modifying an expression regulatory region (or an expression regulatory sequence) so as to reduce the expression of a gene encoding the polypeptide, 3) modifying an amino acid sequence constituting the polypeptide so as to delete or weaken the activity of the polypeptide (e.g., deleting / substituting / adding one or more amino acids in the amino acid sequence), or 4) modifying a gene sequence encoding the polypeptide so as to delete or weaken the activity of the polypeptide (e.g., modifying the gene sequence encoding the polypeptide so as to encode a polypeptide modified so as to delete or weaken the activity of the polypeptide). 5) modifying the base sequence encoding the start codon or 5'UTR region of the gene transcript encoding a polypeptide; 6) introducing an antisense oligonucleotide (e.g., antisense RNA) that binds complementarily to the gene transcript encoding a polypeptide; 7) adding a sequence complementary to the Shine-Dalgarno sequence before the Shine-Dalgarno sequence of the gene encoding a polypeptide so that a secondary structure that makes ribosome attachment impossible is formed; 8) adding a promoter to reverse transcribe the 3' end of the ORF (open reading frame) of the gene sequence encoding a polypeptide (Reverse transcription engineering, RTE); or 9) a combination of two or more selected from the above 1) to 8), but is not particularly limited thereto.
[0067] For example, 1) deleting a part or the whole of the gene encoding the polypeptide may be carried out by deleting the entire polynucleotide encoding the endogenous target polypeptide in a chromosome, or by replacing it with a polynucleotide lacking some nucleotides or a marker gene.
[0068] In addition, the expression regulatory region (or expression regulatory sequence) may be modified by generating a mutation in the expression regulatory region (or expression regulatory sequence) by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, or by substituting a sequence having a lower activity. The expression regulatory region includes, but is not limited to, a promoter, an operator sequence, a sequence encoding a ribosome binding site, and a sequence regulating the termination of transcription and translation.
[0069] In addition, the nucleotide sequence encoding the start codon or 5'UTR region of the gene transcription product encoding the polypeptide can be modified, for example, by substituting a nucleotide sequence encoding another start codon that has a lower expression rate of the polypeptide compared to the endogenous start codon, but is not limited to this.
[0070] Furthermore, the modification of the amino acid sequence or polynucleotide sequence of 4) and 5) above can be performed by, but is not limited to, generating sequence mutations in the amino acid sequence of the polypeptide or the polynucleotide sequence encoding the polypeptide by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, so that the activity of the polypeptide is weakened, or by replacing the sequence with an amino acid sequence or polynucleotide sequence improved to have a lower activity, or an amino acid sequence or polynucleotide sequence improved to have no activity. For example, gene expression can be inhibited or weakened by, but is not limited to, introducing a mutation into a polynucleotide sequence to form a stop codon.
[0071] 6) Introduction of an antisense oligonucleotide (e.g., antisense RNA) that binds complementarily to the gene transcription product encoding the polypeptide may be carried out, for example, as described in Non-Patent Document 16.
[0072] 7) Adding a sequence complementary to the Shine-Dalgarno sequence before the Shine-Dalgarno sequence of a gene encoding a polypeptide so that a secondary structure is formed that makes ribosome attachment impossible may be achieved by making mRNA translation impossible or slowing down the rate.
[0073] 8) Adding a promoter to the 3' end of the ORF (open reading frame) of a gene sequence encoding a polypeptide so as to reverse transcribe the promoter (Reverse transcription engineering, RTE) may be carried out by creating an antisense nucleotide complementary to the gene transcript encoding the polypeptide to attenuate the activity.
[0074] The recombinant microorganism of the present application is selected from the group consisting of Corynebacterium glutamicum, Corynebacterium crudilactis, Corynebacterium deserti, Corynebacterium efficiens, Corynebacterium callunae, Corynebacterium stationis, Corynebacterium singulare, Corynebacterium halotolerans, Corynebacterium striatum, Corynebacterium ammoniagenes, and Corynebacterium ammoniagenes, Corynebacterium pollutisoli, Corynebacterium imitans, Corynebacterium testudinoris or Corynebacterium flavescens, and more specifically, Corynebacterium glutamicum, but is not limited to these.
[0075] The recombinant microorganism of the present application may have an increased or improved ability to produce L-glutamic acid compared to an unmodified microorganism.
[0076] Another aspect of the present application provides a method for producing L-glutamic acid, comprising the step of culturing in a medium an L-glutamic acid-producing recombinant Corynebacterium sp. microorganism comprising an SbtA protein or a polynucleotide encoding an SbtA protein.
[0077] The "SbtA protein", the "polynucleotide encoding the SbtA protein" and the "recombinant microorganism" are as described above.
[0078] The SbtA protein is derived from, but is not limited to, cyanobacteria, as described above.
[0079] The SbtA protein has 90% or more identity to SEQ ID NO:1, but is not limited thereto, as described above.
[0080] The recombinant microorganism of the genus Corynebacterium is, but is not limited to, Corynebacterium glutamicum, as described above.
[0081] The recombinant microorganism may further weaken or delete OdhA, and the OdhA may include, but is not limited to, the amino acid sequence of SEQ ID NO: 29, as described above.
[0082] Furthermore, the recombinant microorganism has an NTG-treated microorganism as a parent strain, but is not limited thereto, as described above.
[0083] In the present application, "culturing" means growing the microorganism under appropriately adjusted environmental conditions. The culturing process of the present application is carried out in a suitable medium and under suitable culture conditions known in the art. Such a culturing process can be easily adjusted and used by a person skilled in the art depending on the strain selected. Specifically, the culturing is batch, continuous, or fed-batch culture, but is not limited thereto.
[0084] In the present application, the term "culture medium" refers to a mixture of nutrients necessary for culturing the microorganism as the main components, and supplies nutrients such as water essential for survival and growth, growth factors, etc. Specifically, the medium and other culture conditions used for culturing the microorganism of the present application may be any medium used for culturing a normal microorganism, and the microorganism of the present application can be cultured in a normal medium containing a suitable carbon source, nitrogen source, phosphorus source, inorganic compounds, amino acids and / or vitamins, etc., under aerobic conditions by adjusting the temperature, pH, etc. Specifically, a culture medium for Corynebacterium strains is disclosed in Non-Patent Document 17.
[0085] The carbon source in the present application may be carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose, etc., sugar alcohols such as mannitol, sorbitol, etc., organic acids such as pyruvic acid, lactic acid, citric acid, etc., amino acids such as glutamic acid, methionine, lysine, etc. Also, natural organic nutrient sources such as starch hydrolysates, molasses, blackstrap molasses, rice bran, cassava, bagasse, corn steeping liquid, etc. may be used, specifically, carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted into reducing sugars) may be used, and any other suitable carbon source may be used. These carbon sources may be used alone or in combination of two or more, but are not limited thereto.
[0086] The nitrogen source may be an inorganic nitrogen source such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, or ammonium nitrate, or an organic nitrogen source such as an amino acid such as glutamic acid, methionine, or glutamine, peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steeping liquid, casein hydrolysate, fish or its decomposition product, or defatted soybean cake or its decomposition product. These nitrogen sources may be used alone or in combination of two or more kinds, but are not limited thereto.
[0087] The phosphorus source may be potassium dihydrogen phosphate, dipotassium hydrogen phosphate, or a sodium-containing salt equivalent thereto. The inorganic compound may be sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, or other suitable compounds, such as amino acids, vitamins, and / or suitable precursors. These components or precursors may be added to the medium in a batch or continuous manner. However, they are not limited thereto.
[0088] In addition, the pH of the medium can be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, and sulfuric acid to the medium in a suitable manner during the cultivation of the microorganism. Furthermore, during the cultivation, foam generation can be suppressed using an antifoaming agent such as fatty acid polyglycol ester. Furthermore, in order to maintain the aerobic state of the medium, oxygen or an oxygen-containing gas may be injected into the medium, and in order to maintain the anaerobic and microaerobic state, no gas may be injected, and nitrogen, hydrogen, or carbon dioxide gas may be injected, but is not limited thereto.
[0089] The temperature of the medium is 20° C. to 45° C., specifically, but not limited to, 25° C. to 40° C. The culture period is continued until a desired amount of useful substance is produced, specifically, but not limited to, 10 hours to 160 hours.
[0090] L-glutamic acid produced by the above culture may be excreted into the medium or may remain within the cells without being excreted.
[0091] The method for producing L-glutamic acid of the present application may further include, prior to the culturing step, a step of preparing a recombinant Corynebacterium microorganism that produces L-glutamic acid, or a step of preparing a medium for culturing the recombinant microorganism.
[0092] Furthermore, the method for producing L-glutamic acid of the present application may further comprise a step of recovering L-glutamic acid from the recombinant microorganism or the medium after the culturing step.
[0093] The method for recovering the L-glutamic acid may be a method for recovering the target L-glutamic acid using a suitable method known in the art depending on the method for culturing the microorganism of the present application, such as batch, continuous, fed-batch culture, etc. For example, centrifugation, filtration, anion exchange chromatography, crystallization, HPLC, etc. may be used, and the target L-glutamic acid can be recovered from the medium or the microorganism using a suitable method known in the art.
[0094] The recovery step may also include a purification step, which may be carried out using any suitable method known in the art.
[0095] As described above, the recovered L-glutamic acid may be in a purified form or may be a microbial fermentation liquid containing L-glutamic acid, but is not limited thereto.
[0096] Yet another aspect of the present application provides a composition for producing L-glutamic acid, comprising an L-glutamic acid producing recombinant Corynebacterium microorganism comprising an SbtA protein or a polynucleotide encoding the SbtA protein, or a medium in which the recombinant microorganism has been cultured.
[0097] The "SbtA protein", "polynucleotide encoding the SbtA protein", "recombinant microorganism" and "medium" are as described above.
[0098] The composition of the present application may further comprise any suitable excipient that is commonly used in compositions for producing L-glutamic acid, such as, for example, a preservative, a wetting agent, a dispersing agent, a suspending agent, a buffer, etc. Examples of suitable antibacterial agents include, but are not limited to, agents, stabilizers, and isotonicity agents. EXAMPLES
[0099] The present application will be described in more detail below with reference to examples. However, these examples are merely preferred embodiments illustrating the present application, and the present application is not limited thereto. In addition, technical matters not described in this specification are fully understood and easily implemented by skilled engineers in the technical field of the present application or a similar technical field. EXAMPLES
[0100] Preparation of Plasmid A plasmid (pDCM2, FIG. 1, SEQ ID NO: 32) for introducing and replacing genes into the Corynebacterium chromosome was designed, and the plasmid was synthesized using the gene synthesis service of Vinyx Co., Ltd. Referring to a paper on the commonly known sacB system [Non-Patent Document 18], the plasmid was designed to contain a restriction enzyme that can be easily used for cloning. The pDCM2 plasmid synthesized in this way has the following characteristics.
[0101] 1) Since it has a replication origin that functions only in E. coli, it has the characteristic that it is capable of self-replication in E. coli but is unable to self-replicate in Corynebacterium.
[0102] 2) It has a kanamycin resistance gene as a selection marker.
[0103] 3) It has the levan sucrose gene (sacB) as a secondary positive selection marker.
[0104] 4) The final strain does not retain any genetic information derived from the pDCM2 plasmid. EXAMPLES
[0105] Construction of a cyanobacterial bicarbonate transporter expression vector. The bicarbonate (HCO3 - In order to confirm whether the introduction of the sbtA and bicA genes encoding the transporters into the strain would improve L-glutamic acid production, an expression vector for sbtA or bicA was first constructed.
[0106] In order to introduce the two aforementioned genes into Corynebacterium glutamicum, we synthesized a sequence (sequence number 2) of sbtA (sequence number 3) derived from Synechocystis sp. PCC6803 that was codon-optimized for Corynebacterium glutamicum, and a sequence (sequence number 5) of bicA (sequence number 6) derived from PCC6803 that was codon-optimized for Corynebacterium glutamicum.
[0107] Furthermore, the pDCM2 vector was used to introduce the two genes described above, and the CJ7 synthetic promoter was used as the expression promoter (Patent Documents 9 and 10).
[0108] Specifically, the pDCM2-△CglE0286::CJ7-sbtA vector and the pDCM2-△CglE0085::CJ7-bicA vector were constructed by using the BBD29_01410 (hereinafter referred to as CglE0286) and BBD29_00440 (hereinafter referred to as CglE0085) sites of Corynebacterium glutamicum transposase or integrase at the positions where homologous recombination occurs in the chromosome.
[0109] Specifically, using the chromosomal DNA of Corynebacterium glutamicum ATCC13869 as a template, the upstream and downstream gene fragments of CglE0286, where homologous recombination of the chromosome occurs, were obtained by PCR using the primer sets of SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10. TM Pfu-X DNA polymerase was used, and the PCR amplification conditions were as follows: denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds, followed by a polymerization reaction at 72°C for 5 minutes.
[0110] The amplified upstream and downstream regions of CglE0286, and the chromosomal transformation vector pDCM2 cleaved with EcoRI and SalI restriction enzymes were cloned by the Gibson assembly method (Non-Patent Document 19) to obtain a recombinant plasmid named pDCM2-△CglE0286. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar amounts, and then storing at 50°C for 1 hour.
[0111] PCR was performed using the synthesized CJ7-sbtA of SEQ ID NO: 11 as a template and primers of SEQ ID NO: 12 and SEQ ID NO: 13 to obtain a CJ7-sbtA gene fragment by PCR. TM Pfu-X DNA polymerase was used, and the PCR amplification conditions were as follows: denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds, followed by a polymerization reaction at 72°C for 5 minutes.
[0112] The amplified CJ7-sbtA and the chromosomal transformation vector pDCM2-△CglE0286 cut with ScaI restriction enzyme were cloned by the Gibson assembly method to obtain a recombinant plasmid named pDCM2-△CglE0286::CJ7-sbtA. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar amount, and then storing at 50℃ for 1 hour.
[0113] In addition, using the chromosomal DNA of Corynebacterium glutamicum ATCC13869 as a template, and primer sets of SEQ ID NO: 14 and SEQ ID NO: 15, and SEQ ID NO: 16 and SEQ ID NO: 17, gene fragments of the upstream and downstream regions of CglE0085, where homologous recombination of the chromosome occurs, were obtained by PCR. TM Pfu-X DNA polymerase was used, and the PCR amplification conditions were as follows: denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds, followed by a polymerization reaction at 72°C for 5 minutes.
[0114] The amplified upstream and downstream regions of CglE0085 and the chromosomal transformation vector pDCM2 digested with EcoRI and SalI restriction enzymes were cloned by the Gibson assembly method to obtain a recombinant plasmid named pDCM2-△CglE0085. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar amounts, and then storing at 50℃ for 1 hour.
[0115] PCR was performed using the synthesized CJ7-bicA of SEQ ID NO: 18 as a template and primers of SEQ ID NO: 12 and SEQ ID NO: 13 to obtain a CJ7-bicA gene fragment. TM Pfu-X DNA polymerase was used, and the PCR amplification conditions were as follows: denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds, followed by a polymerization reaction at 72°C for 5 minutes.
[0116] The amplified CJ7-bicA and the chromosomal transformation vector pDCM2-△CglE0085 cut with ScaI restriction enzyme were cloned by the Gibson assembly method to obtain a recombinant plasmid named pDCM2-△CglE0085::CJ7-bicA. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar amount, and then storing at 50℃ for 1 hour.
[0117] The primer sequences used here are shown in Table 1.
[0118] [Table 1]
[0119] The pDCM2-ΔCglE0286::CJ7-sbtA vector and the pDCM2-ΔCglE0085::CJ7-bicA vector thus prepared were introduced into the strains in the following Examples. EXAMPLES
[0120] Preparation of an L-glutamic acid producing strain derived from wild-type Corynebacterium glutamicum and preparation of a bicarbonate transporter-introduced strain Example 3-1: Preparation of a Corynebacterium glutamicum strain capable of producing L-glutamic acid derived from wild-type Corynebacterium glutamicum In order to prepare a strain capable of producing L-glutamic acid derived from Corynebacterium glutamicum ATCC13869, a Corynebacterium glutamicum ATCC13869△odhA strain in which the odhA gene was deleted was prepared based on the prior art document (Non-Patent Document 20).
[0121] Specifically, for the deletion of odhA, the upstream and downstream regions of the odhA gene were obtained by PCR using the chromosomal DNA of Corynebacterium glutamicum ATCC13869 as a template and the primer sets of SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, and SEQ ID NO: 22. Solg was used as the polymerase. TMPfu-X DNA polymerase was used, and the PCR amplification conditions were as follows: denaturation at 95°C for 5 minutes, followed by 30 cycles of denaturation at 95°C for 30 seconds, annealing at 58°C for 30 seconds, and polymerization at 72°C for 60 seconds, followed by a polymerization reaction at 72°C for 5 minutes.
[0122] The amplified upstream and downstream regions of odhA and the chromosomal transformation vector pDCM2 digested with SmaI restriction enzyme were cloned by the Gibson assembly method to obtain a recombinant plasmid named pDCM2-△odhA. Cloning was performed by mixing the Gibson assembly reagent and each gene fragment in the calculated molar amounts and then storing at 50°C for 1 hour.
[0123] The pDCM2-△odhA vector was transformed into Corynebacterium glutamicum ATCC13869 by electroporation, and then a secondary crossover process was performed to obtain a strain in which the odhA gene was deleted on the chromosome. The presence or absence of gene deletion was confirmed by PCR using SEQ ID NO: 23 and SEQ ID NO: 24 and genome sequencing, and the strain was named ATCC13869△odhA.
[0124] The primer sequences used here are shown in Table 2.
[0125] [Table 2]
[0126] Example 3-2: Preparation of a wild-type Corynebacterium glutamicum-derived strain capable of producing L-glutamic acid by introducing a bicarbonate transporter The pDCM2-△CglE0286CJ7-sbtA vector and the pDCM2-△CglE0085::CJ7-bicA vector prepared in Example 2 were introduced into the ATCC13869△odhA strain prepared in Example 3-1, and the effect of introducing a bicarbonate transporter on L-glutamic acid production ability was confirmed.
[0127] Specifically, the pDCM2-△CglE0286::CJ7-sbtA vector of Example 2 was transformed into the Corynebacterium glutamicum ATCC13869△odhA strain by electroporation, and then a secondary crossover process was performed to obtain a strain in which the CJ7-sbtA gene was introduced at the CglE0286 position on the chromosome.
[0128] The genetic manipulation was confirmed by PCR and genome sequencing using sequence numbers 25 and 26, which respectively amplify the external sites of the upstream and downstream regions of the homologous recombination into which the CJ7-sbtA gene was introduced, and the resulting strain was named CA02-1474.
[0129] In addition, the pDCM2-△CglE0085::CJ7-bicA vector of Example 2 was transformed into the Corynebacterium glutamicum ATCC13869△odhA strain by electroporation, and then a secondary crossover process was performed to obtain a strain in which the CJ7-bicA gene was introduced at the CglE0085 position on the chromosome.
[0130] The genetic manipulation was confirmed by PCR and genome sequencing using sequence numbers 27 and 28, which respectively amplify the external sites upstream and downstream of the homologous recombination into which the CJ7-bicA gene was introduced, and the resulting strain was named CA02-1475.
[0131] The primer sequences used here are shown in Table 3.
[0132] [Table 3]
[0133] The ATCC13869△odhA strain was used as a control, and the CA02-1474 and CA02-1475 strains prepared as described above were cultured in the following manner to confirm their L-glutamic acid producing abilities.
[0134] The strain was inoculated onto a plate medium as a seed medium and cultured at 30°C for 20 hours. Then, one platinum loop of the strain was inoculated into a 250-mL corner baffle flask containing 25 mL of the next production medium, and cultured with shaking at 30°C and 200 rpm for 40 hours. After the culture was completed, the amount of L-glutamic acid produced was measured using high-performance liquid chromatography (HPLC). The measurement results are shown in Table 4. <Seed medium> Glucose 1%, meat juice 0.5%, polypeptone 1%, sodium chloride 0.25%, yeast extract 0.5%, agar 2%, urea 0.2%, pH 7.2 <Production medium> Raw sugar 6%, calcium carbonate 5%, ammonium sulfate 2.25%, potassium dihydrogen phosphate 0.1%, magnesium sulfate 0.04%, ferrous sulfate 10 mg / L, thiamine hydrochloride 0.2 mg / L, biotin 50 μg / L
[0135] [Table 4]
[0136] As shown in Table 4, it was confirmed that the concentration of L-glutamic acid was significantly increased in CA02-1474 introduced with the sbtA gene compared to the ATCC13869△odhA strain or the CA02-1475 strain introduced with the bicA gene. CA02-1474 was deposited with the Korea Microorganism Collection, a depository institution under the Budapest Treaty, on July 28, 2020 under the accession number KCCM12775P. EXAMPLES
[0137] Preparation of Corynebacterium glutamicum strain having L-glutamic acid producing ability derived from N-methyl-N'-nitro-N-nitrosoguanidine (NTG) mutant strain into which bicarbonate transporter has been introduced In order to confirm whether the gene exerts the same effect in NTG mutant Corynebacterium strains with improved L-glutamic acid producing ability in addition to wild-type Corynebacterium strains, the gene was introduced into the KFCC11074 strain (Patent Document 8), which is known as an L-glutamic acid producing NTG mutant strain.
[0138] The pDCM2-△CglE0286::CJ7-sbtA vector of Example 2 was transformed into the KFCC11074 strain by electroporation, and then a second crossover process was performed to obtain a strain with the gene introduced into the chromosome. The genetic manipulation was confirmed by PCR and genome sequencing using SEQ ID NO: 25 and SEQ ID NO: 26, and the strain was named CA02-1476.
[0139] Fermentation titer experiments were carried out using the prepared CA02-1476 and Corynebacterium glutamicum KFCC11074 strains as follows.
[0140] The strain was inoculated onto a plate medium as a seed medium and cultured at 30°C for 20 hours. Then, one platinum loop of the strain was inoculated into a 250-mL corner baffle flask containing 25 mL of the next production medium, and cultured with shaking at 30°C and 200 rpm for 40 hours. After the culture was completed, the amount of L-glutamic acid produced was measured using high-performance liquid chromatography (HPLC). The measurement results are shown in Table 5. <Seed medium> Glucose 1%, meat juice 0.5%, polypeptone 1%, sodium chloride 0.25%, yeast extract 0.5%, agar 2%, urea 0.2%, pH 7.2 <Production medium> Raw sugar 6%, calcium carbonate 5%, ammonium sulfate 2.25%, potassium dihydrogen phosphate 0.1%, magnesium sulfate 0.04%, ferrous sulfate 10 mg / L, thiamine hydrochloride 0.2 mg / L, biotin 500 μg / L
[0141] [Table 5]
[0142] As shown in Table 5, it was confirmed that the concentration of L-glutamic acid in the CA02-1476 strain was increased by 34.8% compared to the KFCC11074 strain.
[0143] From the above description, a person skilled in the art to which the present application pertains will understand that the present application can be implemented in other specific forms without changing its technical ideas or essential features. It should be understood that the above examples are merely illustrative and not limiting. The present application should be interpreted as including all modifications and variations derived from the meaning and scope of the claims and their equivalent concepts, rather than the specification.
[0144] TIFF0007584632000006.tif217170
Claims
1. A recombinant microorganism of the genus Corynebacterium having an ability to produce L-glutamic acid, comprising an SbtA protein or a polynucleotide encoding the SbtA protein.
2. The recombinant microorganism of claim 1 , wherein the protein is derived from a Cyanobacteria.
3. The recombinant microorganism of claim 1 , wherein the protein comprises an amino acid sequence of SEQ ID NO:1 or having 90% or more sequence identity thereto.
4. The recombinant microorganism according to claim 1 , wherein the recombinant microorganism of the genus Corynebacterium is Corynebacterium glutamicum.
5. The recombinant microorganism according to claim 1 , wherein the activity of the OdhA protein in the recombinant microorganism is further attenuated.
6. A method for producing L-glutamic acid, comprising the step of culturing in a medium a recombinant microorganism of the genus Corynebacterium having L-glutamic acid producing ability, which contains an SbtA protein or a polynucleotide encoding the SbtA protein.
7. The method of claim 6 , wherein the protein is derived from cyanobacteria.
8. The method of claim 6, wherein the protein comprises an amino acid sequence of SEQ ID NO:1 or an amino acid sequence having 90% or more sequence identity thereto.
9. The method according to claim 6, wherein the recombinant Corynebacterium microorganism is Corynebacterium glutamicum.
10. The method according to claim 6, further comprising recovering L-glutamic acid from the recombinant microorganism or the culture medium.
11. The method according to claim 6 , wherein the recombinant microorganism further weakens the activity of the OdhA protein.
Citation Information
Patent Citations
Method for producing l-amino acid
JP2010041920A
Microorganism producing glutamic acid and process for preparation glutamic acid using the same
KR100292299B1
Novel promoter nucleic acid derived from corynebacterium genus bacteria, expression cassette comprising the promoter and vector comprising the cassette, host cell comprising the vector and method for expressing a gene using the cell
KR100620092B1
Promoter and uses thereof
US10273491B2
Promoter and use thereof
US10584338B2
